Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 17/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 4/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585698 | 0.85 | ATR (0.65) | ATRMAPK1PRKDCIKBKETBK1 | |
| SCHEMBL318797 | 0.80 | ATR (0.68) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL27912650 | 0.79 | ATR (0.48) | ATRMAPK1PRKDCPLAUIKBKE | |
| SCHEMBL11908281 | 0.77 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL11908296 | 0.77 | ATR (0.67) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL23703073 | 0.76 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL3983358 | 0.76 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL11906967 | 0.76 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL30048631 | 0.76 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL11906430 | 0.75 | ATR (0.64) | ATRPRKDCATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2066676-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008036272-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036272-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885MAPK1 216/4885PRKDC 9/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885MAPK1 216/4885PRKDC 9/4885 |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | MET, RET, ABL1 | ATR 1468/4885MAPK1 718/4885PRKDC 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.